{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T14:11:32Z","timestamp":1764771092593,"version":"3.46.0"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_fhep-2019-0021_abs_001_w2aab3b7b1b1b6b1aab1c17b1Aa\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Quantify the value of functional status (FS) improvements consistent in magnitude with improvements due to levodopa-carbidopa intestinal gel (LCIG) treatment, among the advanced Parkinson\u2019s disease (APD) population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_fhep-2019-0021_abs_002_w2aab3b7b1b1b6b1aab1c17b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Health Economic Medical Innovation Simulation (THEMIS), a microsimulation that estimates future health conditions and medical spending, was used to quantify the health and cost burden of disability among the APD population, and the value of quality-adjusted life-years gained from FS improvement due to LCIG treatment compared to standard of care (SoC). A US-representative Parkinson\u2019s disease (PD)-comparable cohort was constructed in THEMIS based on observed PD patient characteristics in a nationally representative dataset. APD was defined from the literature and clinical expert input. The PD and APD cohorts were followed from 2010 over their remaining lifetimes. All individuals were ages 65 and over at the start of the simulation. To estimate the value of FS improvement due to LCIG treatment, decreases in activities of daily living (ADL) limitations caused by LCIG treatment were calculated using data from a randomized, controlled, double-blind, double-dummy clinical trial and applied to the APD population in THEMIS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_fhep-2019-0021_abs_003_w2aab3b7b1b1b6b1aab1c17b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Total burden of disability associated with APD was $17.7 billion (B). From clinical trial data, LCIG treatment versus SoC lowers the odds of difficulties in walking, dressing, and bathing by 76%, 42% and 39%, respectively. Among the APD population, these reductions generated $2.6B in value to patients and cost savings to payers. The added value was 15% of the burden of disability associated with APD and offsets 15% of the cost of LCIG treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_fhep-2019-0021_abs_004_w2aab3b7b1b1b6b1aab1c17b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>FS improvements, consistent with improvements due to LCIG treatment, in the APD population created health benefits and reduced healthcare costs in the US.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/fhep-2019-0021","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T15:09:07Z","timestamp":1606748947000},"page":"1-23","source":"Crossref","is-referenced-by-count":3,"title":["The Social Value of Improvement in Activities of Daily Living among the Advanced Parkinson\u2019s Disease Population"],"prefix":"10.1515","volume":"23","author":[{"given":"Jeffrey","family":"Sullivan","sequence":"first","affiliation":[{"name":"PRECISIONheor , 11100 Santa Monica Boulevard, Suite 500 , Los Angeles , CA 90025 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany M.","family":"Shih","sequence":"additional","affiliation":[{"name":"PRECISIONheor , 11100 Santa Monica Boulevard, Suite 500 , Los Angeles , CA 90025 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"van Eijndhoven","sequence":"additional","affiliation":[{"name":"PRECISIONheor , 11100 Santa Monica Boulevard, Suite 500 , Los Angeles , CA 90025 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yash J.","family":"Jalundhwala","sequence":"additional","affiliation":[{"name":"AbbVie, Health Economics and Outcomes Research , 1 North Waukegan Rd, D-GMH1, AP31-1E , North Chicago , IL 60064 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darius N.","family":"Lakdawalla","sequence":"additional","affiliation":[{"name":"PRECISIONheor , 11100 Santa Monica Boulevard, Suite 500 , Los Angeles , CA 90025 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Zadikoff","sequence":"additional","affiliation":[{"name":"AbbVie, Health Economics and Outcomes Research , 1 North Waukegan Rd, D-GMH1, AP31-1E , North Chicago , IL 60064 , USA"},{"name":"Feinberg School of Medicine, Northwestern University , Abbott Hall Suite 1123, 710\u00a0N Lake Shore Drive , Chicago , IL 60611 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Benner","sequence":"additional","affiliation":[{"name":"PRECISIONheor , 11100 Santa Monica Boulevard, Suite 500 , Los Angeles , CA 90025 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"Marshall","sequence":"additional","affiliation":[{"name":"AbbVie, Health Economics and Outcomes Research , 1 North Waukegan Rd, D-GMH1, AP31-1E , North Chicago , IL 60064 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita R.","family":"Sail","sequence":"additional","affiliation":[{"name":"AbbVie, Health Economics and Outcomes Research , 1 North Waukegan Rd, D-GMH1, AP31-1E , North Chicago , IL 60064 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"2025120313470683995_j_fhep-2019-0021_ref_001_w2aab3b7b1b1b6b1ab2b3b1Aa","unstructured":"American Thoracic Society. 2007. \u201cFunctional Status.\u201d American Thoracic Society. Also available at https:\/\/qol.thoracic.org\/sections\/key-concepts\/functional-status.html (accessed September 2)."},{"key":"2025120313470683995_j_fhep-2019-0021_ref_002_w2aab3b7b1b1b6b1ab2b3b2Aa","unstructured":"Antonini, A., O. Per, L. Kleinman, A. Skalicky, T. Marshall, K. Sail, and K. Onuk. 2015. \u201cImplementing a Delphi Panel to Improve Understanding of Patient Characteristics of Advanced Parkinson\u2019s Disease [abstract].\u201d In Implementing a Delphi Panel to improve understanding of patient characteristics of Advanced Parkinson\u2019s disease, San Diego, CA, June 14\u201318, 2015."},{"key":"2025120313470683995_j_fhep-2019-0021_ref_003_w2aab3b7b1b1b6b1ab2b3b3Aa","doi-asserted-by":"crossref","unstructured":"Chan, L., S. Beaver, R. F. MacLehose, A. Jha, M. Maciejewski, and J.\u00a0N. Doctor. 2002. \u201cDisability and Health Care Costs in the Medicare Population.\u201d Archives of Physical Medicine and Rehabilitation 83 (9): 1196\u2013201, https:\/\/doi.org\/10.1053\/apmr.2002.34811.","DOI":"10.1053\/apmr.2002.34811"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_004_w2aab3b7b1b1b6b1ab2b3b4Aa","unstructured":"Congressional Budget Office. 2013. \u201cRising Demand for Long-Term Services and Supports for Elderly People.\u201d Congressional Budget Office. Also available at https:\/\/www.cbo.gov\/sites\/default\/files\/113th-congress-2013-2014\/reports\/44363-LTC.pdf (accessed December 11)."},{"key":"2025120313470683995_j_fhep-2019-0021_ref_005_w2aab3b7b1b1b6b1ab2b3b5Aa","doi-asserted-by":"crossref","unstructured":"de Lau, L. M., and M. M. Breteler. 2006. \u201cEpidemiology of Parkinson\u2019s Disease.\u201d The Lancet Neurology 5 (6): 525\u201335, https:\/\/doi.org\/10.1016\/S1474-4422(06)70471-9.","DOI":"10.1016\/S1474-4422(06)70471-9"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_006_w2aab3b7b1b1b6b1ab2b3b6Aa","doi-asserted-by":"crossref","unstructured":"Dorsey, E. R., R. Constantinescu, J.\u00a0P. Thompson, K. M. Biglan, R. G. Holloway, K. Kieburtz, F. J. Marshall, B. M. Ravina, G. Schifitto, A. Siderowf, and C. M. Tanner. 2007. \u201cProjected Number of People with Parkinson Disease in the Most Populous Nations, 2005 through 2030.\u201d Neurology 68 (5): 384\u20136, https:\/\/doi.org\/10.1212\/01.wnl.0000247740.47667.03.","DOI":"10.1212\/01.wnl.0000247740.47667.03"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_007_w2aab3b7b1b1b6b1ab2b3b7Aa","doi-asserted-by":"crossref","unstructured":"Eber, M. R., D. P. Goldman, D. N. Lakdawalla, T. J. Philipson, D. Pritchard, M. Huesch, N. Summers, M. T. Linthicum, J. Sullivan, and R. W. Dubois. 2015. \u201cClinical Evidence Inputs to Comparative Effectiveness Research Could Impact the Development of Novel Treatments.\u201d Journal of Comparative Effectiveness Research 7: 1\u201311, https:\/\/doi.org\/10.2217\/cer.15.9.","DOI":"10.2217\/cer.15.9"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_008_w2aab3b7b1b1b6b1ab2b3b8Aa","doi-asserted-by":"crossref","unstructured":"Fong, J.\u00a0H., O. S. Mitchell, and B. S. Koh. 2015. \u201cDisaggregating Activities of Daily Living Limitations for Predicting Nursing Home Admission.\u201d Health Services Research 50 (2): 560\u201378, https:\/\/doi.org\/10.1111\/1475-6773.12235.","DOI":"10.1111\/1475-6773.12235"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_009_w2aab3b7b1b1b6b1ab2b3b9Aa","doi-asserted-by":"crossref","unstructured":"Goldman, D. P., D. Cutler, J.\u00a0W. Rowe, P. C. Michaud, J. Sullivan, D. Peneva, and S. J. Olshansky. 2013. \u201cSubstantial Health and Economic Returns from Delayed Aging may Warrant a New Focus for Medical Research.\u201d Health Affairs 32 (10): 1698\u2013705, https:\/\/doi.org\/10.1377\/hlthaff.2013.0052.","DOI":"10.1377\/hlthaff.2013.0052"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_010_w2aab3b7b1b1b6b1ab2b3c10Aa","doi-asserted-by":"crossref","unstructured":"Johnson, S. J., M. D. Diener, A. Kaltenboeck, H. G. Birnbaum, and A. D. Siderowf. 2013a. \u201cAn Economic Model of Parkinson\u2019s Disease: Implications for Slowing Progression in the United States.\u201d Movement Disorders 28 (3): 319\u201326, https:\/\/doi.org\/10.1002\/mds.25328.","DOI":"10.1002\/mds.25328"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_011_w2aab3b7b1b1b6b1ab2b3c11Aa","doi-asserted-by":"crossref","unstructured":"Johnson, S. J., K. Anna, M. Diener, H. G. Birnbaum, E. Grubb, J. Castelli-Haley, and A. D. Siderowf. 2013b. \u201cCosts of Parkinson\u2019s Disease in a Privately Insured Population.\u201d PharmacoEconomics 31 (9): 799\u2013806, https:\/\/doi.org\/10.1007\/s40273-013-0075-0.","DOI":"10.1007\/s40273-013-0075-0"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_012_w2aab3b7b1b1b6b1ab2b3c12Aa","doi-asserted-by":"crossref","unstructured":"Kaltenboeck, A., S. J. Johnson, M. R. Davis, H. G. Birnbaum, C. A. Carroll, M. L. Tarrants, and A. D. Siderowf. 2012. \u201cDirect Costs and Survival of Medicare Beneficiaries with Early and Advanced Parkinson\u2019s Disease.\u201d Parkinsonism & Related Disorders 18 (4): 321\u20136, https:\/\/doi.org\/10.1016\/j.parkreldis.2011.11.015.","DOI":"10.1016\/j.parkreldis.2011.11.015"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_013_w2aab3b7b1b1b6b1ab2b3c13Aa","doi-asserted-by":"crossref","unstructured":"Kowal, S. L., T. M. Dall, R. Chakrabarti, M. V. Storm, and A. Jain. 2013. \u201cThe Current and Projected Economic Burden of Parkinson\u2019s Disease in the United States.\u201d Movement Disorders 28 (3): 311\u20138, https:\/\/doi.org\/10.1002\/mds.25292.","DOI":"10.1002\/mds.25292"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_014_w2aab3b7b1b1b6b1ab2b3c14Aa","unstructured":"Lakdawalla, D., M. R. Eber, F. M. Forma, J. Sullivan, P. C. Michaud, L. A. Bradley, and D. P. Goldman. 2013. \u201cMeasuring the Value of Better Diabetes Management.\u201d American Journal of Managed Care 19 (2): E11."},{"key":"2025120313470683995_j_fhep-2019-0021_ref_015_w2aab3b7b1b1b6b1ab2b3c15Aa","doi-asserted-by":"crossref","unstructured":"Lakdawalla, D., D. P. Goldman, J. Bhattacharya, M. D. Hurd, G. F. Joyce, and C. W. Panis. 2003. \u201cForecasting the Nursing Home Population.\u201d Medical Care 41 (1): 8\u201320, https:\/\/doi.org\/10.1097\/00005650-200301000-00003.","DOI":"10.1097\/00005650-200301000-00003"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_016_w2aab3b7b1b1b6b1ab2b3c16Aa","doi-asserted-by":"crossref","unstructured":"Leidy, N. K. 1994. \u201cFunctional Status and the Forward Progress of Merry-Go-Rounds: toward a Coherent Analytical Framework.\u201d Nursing Research 43 (4): 196\u2013202, https:\/\/psycnet.apa.org\/doi\/10.1097\/00006199-199407000-00002.","DOI":"10.1097\/00006199-199407000-00002"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_017_w2aab3b7b1b1b6b1ab2b3c17Aa","unstructured":"National Institute of Neurological Disorders and Stroke. 2015. \u201cParkinson\u2019s Disease: Challenges, Progress, and promise.\u201d National Institute of Neurological Disorder and Stroke, National Institutes of Health. Also available at https:\/\/www.ninds.nih.gov\/disorders\/parkinsons_disease\/parkinsons_research.htm (accessed July 1)."},{"key":"2025120313470683995_j_fhep-2019-0021_ref_018_w2aab3b7b1b1b6b1ab2b3c18Aa","doi-asserted-by":"crossref","unstructured":"Neumann, P. J., J.\u00a0T. Cohen, and M. C. Weinstein. 2014. \u201cUpdating Cost-Effectiveness\u00a0\u2014 The Curious Resilience of the $50,000-Per-QALY Threshold.\u201d New England Journal of Medicine 371 (9): 796\u20137, https:\/\/doi.org\/10.1056\/nejmp1405158.","DOI":"10.1056\/NEJMp1405158"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_019_w2aab3b7b1b1b6b1ab2b3c19Aa","doi-asserted-by":"crossref","unstructured":"Olanow, C. W., K. Kieburtz, P. O. Alberto, J. Espay, D. G. Standaert, H. H. Fernandez, A. Vanagunas, A. A. Othman, K. L. Widnell, W. Z. Robieson, Y. Pritchett, K. Chatamra, J. Benesh, R. A Lenz, and A. Antonini. 2014. \u201cContinuous Intrajejunal Infusion of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson\u2019s Disease: a Randomised, Controlled, Double-Blind, Double-Dummy Study.\u201d The Lancet Neurology 13 (2): 141\u20139, https:\/\/doi.org\/10.1016\/s1474-4422(13)70293-x.","DOI":"10.1016\/S1474-4422(13)70293-X"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_020_w2aab3b7b1b1b6b1ab2b3c20Aa","unstructured":"PRECISIONheor. 2019. Technical Documentation: The Health Economic Medical Innovation Simulation - HRS Version. Also available at https:\/\/www.PRECISIONheor.com\/services\/#anchor3 (accessed May 30)."},{"key":"2025120313470683995_j_fhep-2019-0021_ref_021_w2aab3b7b1b1b6b1ab2b3c21Aa","doi-asserted-by":"crossref","unstructured":"Pringsheim, T., N. Jette, A. Frolkis, and T. D. Steeves. 2014. \u201cThe Prevalence of Parkinson\u2019s Disease: A Systematic Review and Meta-Analysis.\u201d Movement Disorders 29 (13): 1583\u201390, https:\/\/doi.org\/10.1002\/mds.25945.","DOI":"10.1002\/mds.25945"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_022_w2aab3b7b1b1b6b1ab2b3c22Aa","doi-asserted-by":"crossref","unstructured":"Shih, T. M., K. R. Sail, Y. J. Jalundhwala, J. Sullivan, E. van Eijndhoven, C. Zadikoff, T. S. Marshall, and D. N. Lakdawalla. 2020. \u201cThe Effect of Functional Status Impairment on Nursing Home Admission Risk Among Patients with Advanced Parkinson\u2019s Disease.\u201d Journal of Medical Economics 23 (3): 297\u2013307, https:\/\/doi.org\/10.1080\/13696998.2019.1693383.","DOI":"10.1080\/13696998.2019.1693383"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_023_w2aab3b7b1b1b6b1ab2b3c23Aa","doi-asserted-by":"crossref","unstructured":"Soh, S. E., M. E. Morris, and J.\u00a0L. McGinley. 2011. \u201cDeterminants of Health-Related Quality of Life in Parkinson\u2019s Disease: A Systematic Review.\u201d Parkinsonism & Related Disorders 17 (1): 1\u20139, https:\/\/doi.org\/10.1016\/j.parkreldis.2010.08.012.","DOI":"10.1016\/j.parkreldis.2010.08.012"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_024_w2aab3b7b1b1b6b1ab2b3c24Aa","doi-asserted-by":"crossref","unstructured":"Standaert, D. G., H. H. Fernandez, P. Odin, R. A. Hauser, A. J. Espay, M. Steiger, S. Chouinard, O. Suchowersky, E. Yakupov, E. P. Merikle, W. Z. Robieson, K. Chatamra, and J. Benesh. 2013. \u201cA Long-Term, Open-Label Study of Levodopa\u2013Carbidopa Intestinal Gel in Advanced Parkinson\u2019s Disease Patients: Functional and Health-Related Quality-Of-Life Endpoints.\u201d Journal of Neurological Sciences 333: e123\u20134, https:\/\/doi.org\/10.1002\/mds.26123.","DOI":"10.1016\/j.jns.2013.07.413"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_025_w2aab3b7b1b1b6b1ab2b3c25Aa","unstructured":"Truven Health Analytics Microdex Solutions. 2016. RedBook Online. Greenwood Village. CO: Truven Health Analytics. ."},{"key":"2025120313470683995_j_fhep-2019-0021_ref_026_w2aab3b7b1b1b6b1ab2b3c26Aa","doi-asserted-by":"crossref","unstructured":"Nuys, V., A. K. Karen, H. Phatak, U. Iloeje, J. Sullivan, D. N. Lakdawalla, E. Vasudeva, and W. Weintraub. 2014. \u201cAbstract 257: A Long-Term Comparison of Clinical and Economic Outcomes with Novel Oral Anti- Coagulants.\u201d Circulation: Cardiovascular Quality and Outcomes 7 (Suppl 1): A257.","DOI":"10.1161\/circoutcomes.7.suppl_1.257"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_027_w2aab3b7b1b1b6b1ab2b3c27Aa","unstructured":"van Reenen, M., and B. Janssen. 2015. \u201cEQ-5D-5L User guide.\u201d EuroQol Research Foundation. Also available at https:\/\/www.euroqol.org\/fileadmin\/user_upload\/Documenten\/PDF\/Folders_Flyers\/EQ-5D-5L_UserGuide_2015.pdf (accessed October 4)."},{"key":"2025120313470683995_j_fhep-2019-0021_ref_028_w2aab3b7b1b1b6b1ab2b3c28Aa","doi-asserted-by":"crossref","unstructured":"Viscusi, W. K., and J.\u00a0E. Aldy. 2003. \u201cThe Value of a Statistical Life: A Critical Review of Market Estimates throughout the World.\u201d Journal of Risk and Uncertainty 27 (1): 5\u201376, https:\/\/doi.org\/10.1023\/A:1025598106257.","DOI":"10.1023\/A:1025598106257"},{"key":"2025120313470683995_j_fhep-2019-0021_ref_029_w2aab3b7b1b1b6b1ab2b3c29Aa","unstructured":"World Health Organization. 2007. \u201cNeurological Disorders: Public Health challenges.\u201d World Health Organization. Also available at https:\/\/www.who.int\/mental_health\/neurology\/flyer_neurological_report.pdf?ua=1 (accessed October 4)."}],"container-title":["Forum for Health Economics &amp; Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/fhep\/ahead-of-print\/article-10.1515-fhep-2019-0021\/article-10.1515-fhep-2019-0021.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/fhep-2019-0021\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/fhep-2019-0021\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T13:48:35Z","timestamp":1764769715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/fhep-2019-0021\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,25]]},"published-print":{"date-parts":[[2021,5,12]]}},"alternative-id":["10.1515\/fhep-2019-0021"],"URL":"https:\/\/doi.org\/10.1515\/fhep-2019-0021","relation":{},"ISSN":["1558-9544","2194-6191"],"issn-type":[{"type":"electronic","value":"1558-9544"},{"type":"print","value":"2194-6191"}],"subject":[],"published":{"date-parts":[[2020,11,25]]}}}